NCT05607420 - Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions

B-cell Non-Hodgkin Lymphoma (B-NHL)

Interventions

BIOLOGICAL

UCART20x22

Allogeneic engineered T-cells expressing anti-CD20 and anti-CD22 Chimeric Antigen Receptors given following a lymphodepletion regimen

BIOLOGICAL

CLLS52

A monoclonal antibody that recognizes a CD52 antigen

Trial Locations (10)

31008

RECRUITING

Universidad de Navarra - Clinica Universidad de Navarra (CUN) - Pamplona, Pamplona

34295

RECRUITING

Centre Hospitalier Universitaire de Montpellier (CHU Montpellier) - Hopital Saint-Eloi, Montpellier

41013

RECRUITING

Hospital Universitario Virgen del Rocio (HUVR) - Instituto de Biomedicina de Sevilla (IBIS), Seville

44093

RECRUITING

Centre Hospitalier Universitaire de Nantes (CHU de Nantes)-Hotel-Dieu, Nantes

60637

RECRUITING

The University of Chicago Medical Center (UCMC), Chicago

69310

RECRUITING

Hospices Civils de Lyon (HCL) - Centre Hospitalier Lyon-Sud, Pierre-Bénite

75010

RECRUITING

Assistance Publique-Hopitaux de Paris (AP-HP) - Hopital Saint-Louis - Centre Integre en Cancerologie, Paris

78704

RECRUITING

Sarah Cannon - St. David South Austin Medical Center, Austin

02114

RECRUITING

Harvard Medical School - Massachusetts General Hospital, Boston

08901

RECRUITING

Rutgers Cancer Institute of New Jersey (CINJ) - New Brunswick, New Brunswick